Literature DB >> 29411096

[Anifrolumab in systemic lupus erythematosus].

A Erler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29411096     DOI： 10.1007/s00393-018-0420-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  5 in total

1.  A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

Authors:  Kenneth C Kalunian; Joan T Merrill; Romeo Maciuca; Jacqueline M McBride; Michael J Townsend; Xiaohui Wei; John C Davis; William P Kennedy
Journal:  Ann Rheum Dis       Date:  2015-06-02       Impact factor: 19.103

Review 2.  Targeting interferons in systemic lupus erythematosus: current and future prospects.

Authors:  Alexis Mathian; Miguel Hie; Fleur Cohen-Aubart; Zahir Amoura
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

3.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

4.  Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.

Authors:  Marko Yurkovich; Kateryna Vostretsova; Wenjia Chen; J Antonio Aviña-Zubieta
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

5.  Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Authors:  Munther Khamashta; Joan T Merrill; Victoria P Werth; Richard Furie; Kenneth Kalunian; Gabor G Illei; Jorn Drappa; Liangwei Wang; Warren Greth
Journal:  Ann Rheum Dis       Date:  2016-03-23       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.